北上腺素剂量报告异质性对败血症休克患者死亡率预测的影响
Sebastian Morales1, Pedro D Wendel-Garcia2, Miguel Ibarra-Estrada3,4
1Departamento de Medicina Intensiva, Facultad de Medicina, Pontificia Universidad Católica de Chile, Avenida Diagonal Paraguay 362, Santiago, Chile.
Critical care (London, England)
|July 3, 2024
概括
诺拉上腺素剂量报告变化影响了败血症休克死亡率的预测. 将基分子标准化改进了风险评估和患者护理,强调了在重症监护中需要一致的报告的必要性.
科学领域:
- 临界护理医学 临界护理医学
- 药理学 药理学是指药理学的学科.
- 临床数据分析 临床数据分析
背景情况:
- 上腺素 (NE) 对于感染性休克管理至关重要,其剂量表明疾病严重程度和死亡风险.
- 不一致的NE剂量报告 (例如,盐与基础分子) 可能导致误解死亡风险,并影响临床决策.
研究的目的:
- 评估异质的诺阿基因林剂量报告对败血症休克患者死亡率预测的影响.
- 为了比较不同NE剂量配方 (比特酸盐,酸盐,基分子) 对28天死亡率的预测准确度.
主要方法:
- 对MIMIC-IV数据库进行了回顾性分析.
- 将NE剂量转换为标准化的基本分子等价物.
- 使用不同NE剂量配方在不同切断点进行28天死亡预测的比较.
主要成果:
- 分析包括4086名败血症休克患者,28天死亡率为39.3%.
- NE剂量报告配方显著改变了死亡率预测;双酸盐和酸盐配方的几率比基分子要低得多.
- 在1μg/kg/min的值下,酸盐 (54%) 和基分子 (83%) 配方之间的预测死亡率显著不同.
结论:
- 不同类型的NE剂量报告极大地影响了败血症休克死亡率的预测.
- 将NE剂量报告到基分子的标准化对于准确的风险分层和改善患者护理至关重要.
- 在重症监护机构中,对NE剂量进行一致的报告实践至关重要.
相关概念视频
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
74
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
74
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419